News Releases

Keyword Search

Apr-12-2021
Oncternal Therapeutics Announces Appointment of Chase Leavitt as General Counsel
Apr-12-2021
Oncternal Therapeutics Announces Presentation of Three Posters at AACR 2021 Virtual Meeting
Mar-18-2021
Oncternal Therapeutics Reports Granting of an Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Mar-11-2021
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2020 Financial Results
Mar-04-2021
Oncternal Therapeutics to Report Fourth Quarter 2020 Financial Results and Provide Business Update
Feb-24-2021
Oncternal Therapeutics to Participate in March Investor Conferences
Feb-22-2021
Oncternal Therapeutics Reports Granting of an Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Jan-28-2021
Oncternal Therapeutics Announces the Appointment of Dr. Rosemary Mazanet to the Board of Directors
Jan-14-2021
Oncternal Therapeutics, Inc. Confirms Lentigen Technology, Inc. to Manufacture Lentiviral Vectors for Its ROR1-targeting CAR-T Cell Therapy Program
Jan-07-2021
Oncternal Therapeutics and Karolinska Institutet Establish Collaboration for Research and Development of ROR1-targeting CAR-T and CAR-NK Cell Therapies